ClinicalTrials.gg
Not yet recruitingNCT07786857SUGAR-LTUpdated Aug 26, 2026

Intraoperative Glycemic Variability and Infectious Complications After Liver Transplantation

An observational study in Liver Transplantation (LT), sponsored by Medical University of Warsaw. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Medical University of Warsaw · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 11 studies in Surgical Wound Infection with a site in Poland — 2 open to participants now, 2 under way, none of them phase 3. Surgical Wound Infection · Poland.

Started
2026
the only one that year
Observational
2 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
Medical University of Warsaw

Among the 11 studies in Surgical Wound Infection with a site in Poland, this one is the only one that started in 2026, is one of 2 observational ones, and was the 11th registered.

Surgical Wound Infection

746 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

2 of the 11 studies in Surgical Wound Infection with a site in Poland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 84 Surgical Wound Infection studies recruiting now, 60 (71%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Surgical Wound Infection with a site in Poland, or all of them as a file.
02

Study summary

This study aims to evaluate whether intraoperative glycemic variability (GV) is independently associated with the risk of infectious complications within 30 days after elective liver transplantation. This is an observational study with no intervention beyond standard perioperative care. Glycemic and clinical outcome data will be obtained from routinely collected medical records of patients undergoing liver transplantation at the 2nd Department of Anesthesiology and Intensive Care, Medical University of Warsaw.

03

Conditions studied

  • Liver Transplantation (LT)

Keywords

  • liver transplantation
  • glycemic variability
  • postoperative infections
  • surgical site infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients undergoing liver transplantation at the 2nd Department of Anesthesiology and Intensive Care, Medical University of Warsaw.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years
  • Elective orthotopic liver transplantation

Exclusion criteria

Exclusion Criteria:

  • Liver retransplantation
  • multi-organ transplantation
  • Urgent/emergency transplantation
  • Active infection under antibiotic treatment at the time of surgery
  • Preoperative systemic inflammatory response syndrome (SIRS)
  • Incomplete intraoperative glycemic data
  • Pregnancy
  • Participation in another interventional study that could affect glycemic control or infection risk
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Occurrence of at least one infectious complication within 30 days after liver transplantation

    Binary outcome (yes/no), including: pneumonia (clinical, radiological, and microbiological criteria), urinary tract infection (clinical symptoms + positive urine culture), surgical site infection per CDC criteria, sepsis/septic shock per Sepsis-3 criteria.

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2027, 11 months later.

Of 65 non-industry observational studies under Surgical Wound Infection, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 53. This study's planned 11 months is below that.

Counting every sponsor, half of 68 studies reached it within 21 months; a quarter within 9 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Aug 26, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07786857
Responsible party
Sponsor
First posted
Aug 26, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Paula Dudek, MD
Contact
paula.dudek@wum.edu.pl
+225992002

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion